pharma · Renal Impairment · Osteoarthritis, Knee / Osteoarthritis, Hip
Tanabe Pharma
Tanabe Pharma is a pharma organization headquartered in Osaka, JP. Primary therapeutic focus areas include Renal Impairment, Osteoarthritis, Knee / Osteoarthritis, Hip. NovaPharmaNews links 4 clinical program(s), 0 drug
Osaka, JP HQ
1678 Founded
104 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Osaka, JP
- Founded
- 1678
- Employees
- 104
- Programs
- 4
- Drugs
- 1
- Patents
- 0
MCI-186
Phase 1 · small molecule · Renal Impairment
MCI-186 for Renal Impairment is a Phase 1 program (small_molecule) at Tanabe Pharma with 1 ClinicalTrials.gov record(s).
Internal code MCI-186-J22
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tanabe Pharma
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Renal Impairment
- Status
- completed
- Trials
- 1